Elon Musk’s brain computer interface company Neuralink has been awarded a Breakthrough Device designation by the United States FDA for their Blindsight device.

Pre-clinical blood cell therapy startup Safi Biotherapeutics has raised $5 million in seed funding led by prominent deep tech venture capital fund J2 Ventures.

MIRA Pharmaceuticals (NASDAQ: MIRA) has officially designated neuropathic pain as the initial and primary indication for their novel oral ketamine analogue.

Atossa Therapeutics (NASDAQ: ATOS) has officially dosed their first patient in their clinical trial partnership with Quantum Leap Healthcare Collaborative.

Modular Medical (NASDAQ: MODD) has been granted official approval from the United States FDA to sell their MODD1 medical device for diabetes patients.

Achieve Life Sciences (NASDAQ:ACHV) has been granted Breakthrough Therapy Designation from the FDA for cytisinicline as a potential treatment for addiction.

Safety Shot (NASDAQ: SHOT) has announced new data analysis from a recent clinical trial that shows significant validation for their proprietary drink.

Fentanyl testing company Safety Strips has entered into a letter of intent with Greenlane Holdings (NASDAQ:GNLN) to become the exclusive distributor in the USA.

Artificial intelligence powered drug discovery startup Enveda has raised $55 million in a Series B financing round.

Caladan Bio is developing next generation bioreactors that are capable of enhancing data capture and improving experimentation for synthetic biology companies.